© 2021 BioMarin. All rights reserved.

Gabor Veres, Ph.D., currently serves as Vice President, Head of Gene Therapy Research. In this role, Dr. Veres focuses on AAV platform discovery and identifying new therapeutic indications in gene therapy.

Dr. Veres has managed biotechnology companies from discovery through late stage development, including cell and gene therapy platform technology. He holds 20 years of experience in the development of cell and gene therapy products for the treatment of severe genetic disorders, HIV and cancer. Dr. Veres joined BioMarin from Bluebird Bio, where he worked as the Vice President of Pre-clinical Research. He initiated and coordinated multiple research programs, including viral gene delivery to correct genetic and acquired diseases, cancer vaccines and oncolytic viruses, he also led several projects from pre-clinical research to clinical development.

Prior to joining Bluebird Bio, Dr. Veres served as Vice President of Research and Development at Applied Genetic Technologies Corporation, a gene therapy company focused on developing treatments for rare conditions of the eye, lung and liver. He also worked as Senior Director at Sangamo, Director of Research at Genthon, Senior Director at CellGenesys Inc. and Director of Research at Novartis/Systemix. Dr. Veres has authored 55 scientific publications.

Our Pipeline

We take on the biggest challenges in rare disease.

Each drug candidate we pursue is guided by a fundamental understanding of the genetics and underlying biology of the condition it will address.

View Now Our Pipeline